Jaguar Health (JAGX) EBITDA Yield: History & Chart

Jaguar Health, Inc.(JAGX)

Biotechnology · San Francisco, CA

$5.80+1.07 (+22.62%)

Delayed quote: Oct 6, 2026, 11:35 AM EDT

About Jaguar Health, Inc.

Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.

San Francisco, CA

47 employees

jaguar.health

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lisa A. Conte

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Jaguar Health, Inc. (JAGX)	$2.52M	N/A	N/A	N/A	N/A
Moleculin Biotech, Inc. (MBRX)vs ›	$2.48M	N/A	N/A	N/A	N/A
bioAffinity Technologies, Inc. (BIAF)vs ›	$2.58M	N/A	N/A	N/A	N/A
FibroBiologics, Inc. Common Stock (FBLG)vs ›	$2.58M	N/A	N/A	N/A	N/A
Nuwellis, Inc. (NUWE)vs ›	$2.62M	N/A	N/A	N/A	N/A
iSpecimen Inc. (ISPC)vs ›	$2.64M	N/A	N/A	N/A	N/A
Creative Medical Technology Holdings, Inc. (CELZ)vs ›	$2.33M	N/A	N/A	N/A	N/A
Onconetix, Inc. (ONCO)vs ›	$2.33M	N/A	N/A	N/A	N/A
GeoVax Labs, Inc. (GOVX)vs ›	$2.33M	N/A	0.00%	0.00%	0.00%
Adagio Medical Holdings, Inc. (ADGM)vs ›	$3.04M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

Jaguar Health, Inc. (JAGX)

$2.52M

N/A

Moleculin Biotech, Inc. (MBRX)vs ›

$2.48M

N/A

bioAffinity Technologies, Inc. (BIAF)vs ›

$2.58M

N/A

FibroBiologics, Inc. Common Stock (FBLG)vs ›

$2.58M

N/A

Nuwellis, Inc. (NUWE)vs ›

$2.62M

N/A

iSpecimen Inc. (ISPC)vs ›

$2.64M

N/A

Creative Medical Technology Holdings, Inc. (CELZ)vs ›

$2.33M

N/A

Onconetix, Inc. (ONCO)vs ›

$2.33M

N/A

GeoVax Labs, Inc. (GOVX)vs ›

$2.33M

N/A

0.00%

Adagio Medical Holdings, Inc. (ADGM)vs ›

$3.04M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

JAGX EBITDA Yield Metrics

JAGX Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics